YOLFTbeta
Xeris Pharmaceuticals Inc

Xeris Pharmaceuticals Inc

XERS · NASDAQ · Healthcare / Drug Manufacturers - Specialty & Generic

16.66USD+0.01 (+0.06%)

Price History

Full chart

Market Stats

Previous Close16.65
Open16.60
Day Range16.31 – 16.76
52-Week Range5.25 – 16.88
Volume3.40M
Market Cap3.04B
P/E (TTM)0.00
Forward P/E85.47
EPS-0.03
Dividend Yield0.00%
Beta0.84
50-Day Avg10.24
200-Day Avg7.78

About

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. John P. Shannon
  • Employees435
  • Headquarters1375 West Fulton Street, Chicago, IL, United States, 60607, USA
  • Websitehttps://www.xerispharma.com

Leadership

  • Mr. John P. ShannonChairman & CEO · b. 1962
  • Mr. Kevin McCullochPresident & COO · b. 1964
  • Mr. Steven M. PieperChief Financial Officer · b. 1977
  • Ms. Beth P. Hecht J.D.Chief Legal Officer & Corporate Secretary · b. 1964
  • Dr. Anh T. Nguyen M.B.A., M.D.Chief Medical Officer · b. 1975
  • Ms. Cristi BarnettVice President of Investor Relations
  • Mr. Brian ConnerSVP of Quality and Chief Compliance & Risk Officer
  • Ms. Kendal KorteSenior Vice President of Human Resources
  • Joshua BennettVice President of Strategy & Business Development

Financials

Income Statement

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.07M1.56M2.46M2.72M2.72M49.59M110.25M163.91M203.07M291.85M
Growth (%)-+44.74%+58.42%+10.43%0.00%+1721.82%+122.32%+48.68%+23.89%+43.72%
Cost of Revenue8.00K4.00K42.00K1.60M1.60M13.32M22.63M28.64M36.83M53.41M
Gross Profit1.07M1.55M2.42M1.12M1.12M36.27M87.61M135.27M166.24M238.43M
Gross Margin99.26%99.74%98.30%41.11%41.11%73.14%79.47%82.52%81.86%81.70%
Operating Expense14.30M28.18M61.77M123.50M123.50M151.43M169.55M179.28M199.88M213.54M
Operating Income-13.23M-26.63M-59.34M-122.38M-122.38M-115.16M-81.94M-44.01M-33.65M24.90M
Operating Margin-1230.79%-1711.38%-2407.46%-4495.96%-4495.96%-232.22%-74.32%-26.85%-16.57%8.53%
EBITDA-13.09M-26.38M-57.22M-119.57M-117.80M-113.67M-69.31M-23.73M-13.99M12.71M
EBITDA Margin-1217.77%-1695.18%-2321.10%-4392.62%-4327.59%-229.21%-62.87%-14.48%-6.89%4.36%
Net Income-13.21M-26.55M-60.08M-125.58M-125.58M-122.72M-94.66M-62.26M-54.84M554.00K
Net Income Margin-1228.74%-1706.56%-2437.32%-4613.52%-4613.52%-247.48%-85.86%-37.98%-27.00%0.19%
R&D10.24M20.17M40.65M60.44M60.44M25.16M20.97M22.34M25.56M31.16M
R&D as % of Total Revenue952.37%1296.02%1649.25%2220.35%2220.35%50.74%19.02%13.63%12.59%10.68%
Interest Expense2.00K2.00K2.54M7.16M7.16M7.18M14.10M26.61M33.17M29.08M
Interest Expense % of Total Revenue0.19%0.13%103.25%263.15%263.15%14.48%12.79%16.23%16.34%9.97%

Balance Sheet

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets33.53M45.00M120.03M108.99M108.99M304.36M344.52M322.60M323.06M383.53M
Total Liabilities65.47M102.83M44.62M94.55M94.55M209.13M299.33M329.38M352.68M369.84M
Total Equity-31.93M-57.83M75.41M14.44M14.44M95.23M45.19M-6.78M-29.61M13.69M
Cash32.27M42.05M45.72M19.52M19.52M67.27M121.97M67.45M71.62M111.04M
Total Debt--40.10M58.30M58.30M88.07M198.06M229.19M271.45M37.76M
Net Debt-32.27M-42.05M-13.83M38.79M38.79M20.80M76.09M161.74M199.83M-73.28M

Cash Flow

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-16.09M-24.66M-56.28M-104.35M-80.56M-95.53M-102.89M-47.02M-36.98M28.63M
Investing Cash Flow-35.00K-700.00K-68.26M-2.38M-27.41M97.96M34.46M-6.00M4.88M-696.00K
Financing Cash Flow3.90M35.14M128.21M80.53M126.06M27.25M127.47M-1.61M36.17M11.39M
Capital Expenditure35.00K700.00K1.51M1.11M377.00K1.08M524.00K2.26M868.00K696.00K
Free Cash Flow-16.12M-25.36M-57.79M-105.45M-80.94M-96.62M-103.42M-49.29M-37.85M27.93M
Dividends Paid---60.68M95.64M25.09M147.05M---
FCF to OCF100.22%102.84%102.68%101.06%100.47%101.14%100.51%104.81%102.35%97.57%
Dividend Paid to FCF----57.55%-118.17%-25.97%-142.19%---

Earnings

Report DateMar 31, 2017May 4, 2017Sep 30, 2017Dec 31, 2017Feb 3, 2018Jun 21, 2018Aug 13, 2018Nov 7, 2018Mar 6, 2019May 9, 2019Aug 6, 2019Nov 7, 2019Mar 11, 2020May 7, 2020Aug 10, 2020Nov 9, 2020Mar 9, 2021May 13, 2021Aug 5, 2021Nov 10, 2021Mar 10, 2022May 11, 2022Aug 10, 2022Nov 9, 2022Mar 8, 2023May 9, 2023Aug 8, 2023Nov 9, 2023Mar 6, 2024May 9, 2024Aug 8, 2024Nov 8, 2024Mar 4, 2025May 8, 2025Aug 7, 2025Nov 6, 2025Mar 2, 2026May 7, 2026Aug 6, 2026Nov 5, 2026
EPS Estimate0.00-0.000.00-0.00-0.88-0.78-0.93-0.76-0.94-1.23-1.13-0.89-0.73-0.52-0.38-0.34-0.30-0.37-0.24-0.24-0.22-0.15-0.16-0.15-0.11-0.10-0.10-0.11-0.09-0.08-0.02-0.04-0.030.010.02-0.010.020.02
EPS Actual-2.29-0.23-3.72-4.43-1.29-4.69-3.07-0.71-0.98-1.07-1.28-1.22-1.23-0.89-0.63-0.35-0.41-0.30-0.41-0.39-0.42-0.25-0.19-0.16-0.10-0.12-0.14-0.09-0.10-0.14-0.10-0.06-0.03-0.06-0.010.000.060.01-0.010.06
Surprise-------248.86%8.97%-5.38%-40.79%-36.17%0.81%-8.85%0.00%13.70%32.69%-7.89%11.76%-36.67%-5.41%-75.00%-4.17%13.64%-6.67%37.50%20.00%-27.27%10.00%0.00%-27.27%-11.11%25.00%-50.00%-50.00%66.67%-65.00%261.45%200.00%-150.00%200.00%
Timing-----After-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap3.04B
Enterprise Value3.14B
Trailing P/E0.00
Forward P/E85.47
Price / Sales8.27
Price / Book62.36
EPS-0.03
Book Value0.267
Revenue (TTM)368.26M
Gross Profit (TTM)321.80M
EBITDA58.94M
Profit Margin-1.76%
Operating Margin12.70%
Return on Equity-27.11%
Return on Assets7.37%
Shares Outstanding182.70M
Shares Float176.52M
Beta0.84
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 7 analystsTarget 17.29
  • Strong Buy
    5
  • Buy
    1
  • Hold
    1

Ownership Breakdown

Institutions
63.60%
Insiders
3.00%
Retail / Other
33.40%

Top Institutional Holders

  • BlackRock Inc
    14.53M7.95%
  • D. E. Shaw & Co LP
    7.80M4.27%
  • Vanguard Capital Management, LLC
    7.34M4.02%
  • State Street Corp
    4.82M2.64%
  • Geode Capital Management, LLC
    4.72M2.58%
  • Nuveen, LLC
    4.39M2.40%
  • Rosalind Advisors, Inc.
    2.91M1.59%
  • Qube Research & Technologies
    2.89M1.58%
  • Vanguard Portfolio Management, LLC
    2.63M1.44%
  • Wellington Management Company LLP
    2.37M1.29%
  • Morgan Stanley - Brokerage Accounts
    2.34M1.28%
  • Legal & General Group PLC
    2.01M1.10%
  • Armistice Capital, LLC
    1.96M1.07%
  • Two Sigma Investments LLC
    1.89M1.03%
  • Parkman Healthcare Partners LLC
    1.81M0.99%
  • Algert Global LLC
    1.74M0.95%
  • Dimensional Fund Advisors, Inc.
    1.70M0.93%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    5.50M3.01%
  • iShares Russell 2000 ETF
    4.34M2.37%
  • Fidelity Small Cap Index
    1.87M1.02%